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Abstract Despite evidence for its efficacy, diagnosis-spe-
cific psychoeducation is not routinely applied. This explor-
atory randomized controlled trial analyses the efficacy of an
easily implementable bifocal diagnosis-mixed group psy-
choeducation in the treatment of severe psychiatric disorders
regarding readmission, compliance and clinical variables, for
example global functioning. Inpatients of the Psychiatric
Hospital of the University of Basel (N = 82) were randomly
assigned to a diagnosis-mixed psychoeducational (PE) or a
non-specific intervention control group. Relatives were
invited to join corresponding family groups. Results at
baseline, 3- and 12-month follow-ups are presented. Better
compliance after 3 months and a lower suicide rate were
significant in favour of PE. For most other outcome variables,
no significant differences, however advantages, in PE were
found. In summary, it can be concluded that diagnosis-mixed
group psychoeducation is effective in the treatment of severe
psychiatric disorders. The effects can be classified as induced
by distinctive psychoeducational elements. Findings similar
to those on psychosis-specific programmes justify clinical
application and further investigation.
Keywords Psychoeducation  Group psychoeducation 
Diagnosis-independent  Diagnosis-mixed
Introduction
Psychoeducation (PE) is defined as a therapeutic interven-
tion that implies the provision of illness- and treatment-
related information, supportive elements and the promotion
of management and coping strategies. It is mainly offered in
groups for psychiatric patients and/or their relatives/carers
[1, 2]. By now, PE is recommended in most evidence-based
guidelines for a variety of diseases [3–5]. Trials and reviews
report favourable effects, for example in depression and
bipolar disorder [6, 7]. The Cochrane-analysis on findings in
schizophrenia—its main application area—has shown a
significant decrease of relapse and readmission rates in the
intervention group. A tendency towards better adherence and
gain of knowledge was found [8]. Family involvement
reduced the relapse rate and readmission rate by 20% com-
pared to PE directed at patients alone, improved social
functioning and decreased relatives’ burden [9–11]. A recent
meta-analysis on psychoeducation in psychotic disorders
revealed significantly reduced relapse and rehospitalization
rates and better knowledge gain at post-treatment up to the
12 months follow-up, if families were included. No effects
on symptoms, functioning and medication adherence were
found. All effects achieved for PE directed at patients alone
were not significant [12]. Meanwhile, new studies have been
published, most of them including family members, and with
significant results regarding various aspects [13]. In the
updated guidelines of the National Institute for Health and
Clinical Excellence (NICE) for the treatment of schizo-
phrenia, the evidence was considered not recent and robust
enough to make a specific recommendation. However,
‘‘related recommendations’’ were given [1].
Even in the treatment of schizophrenia, the employment
of PE in clinical practice falls far short of the recommen-
dations [14, 15]. A survey at all psychiatric hospitals in
Germany, Switzerland and Austria revealed that only 21%
of all schizophrenic inpatients and 2% of their relatives
received PE. As main single reason lack of time and staff
was accused, and the largest factor comprehended ‘‘other
reasons’’, primarily ‘‘not enough patients with the same
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diagnosis available’’. The extremely rare application to
family members has been striking [16]. The analysis con-
cerning anxiety disorders revealed similar results [17].
To facilitate the implementation of psychoeducation in
clinical routine and to consider that its main topics should
be similar for a variety of severe psychiatric diseases [18],
Rabovsky and Stoppe developed a diagnosis-mixed group
programme [19, 20]. To date, only one comparable cur-
riculum is available [21], and the efficacy has not been
tested yet. Considering the evidence for combined pro-
grammes regarding compliance [22], the curriculum inte-
grates cognitive-behavioural and interactive elements
besides pure knowledge transfer, but still focuses on the
provision of information and the promotion of manage-
ment/coping strategies. Insofar, it is in accordance with the
definition of the NICE-Guideline Development Group
(GDG) as well as that of the German expert group [1, 2].
The bifocal programme is based on well-proven disorder-
specific concepts [2, 23]. In contrast to traditional curricula,
patients with all severe psychiatric diseases are admitted,
especially those with schizophrenia, schizoaffective disor-
der, depression, bipolar, personality or anxiety disorders.
Patients with organic brain and addiction disorders were
excluded. The programme for patients consists of 10 ses-
sions, 45–60 min each, and takes place semi-weekly. The
setting is open, with at most 10 participants per group. The
group for relatives is closed, consists of 5 sessions a 90 min,
taking place (bi)weekly. With regard to contents, both pro-
grammes cover the classic psychoeducational topics like
information on psychiatric symptoms and diseases, medi-
cation and other therapeutic options (‘‘information-ses-
sions’’). Special emphasis is placed on cognitive-
behavioural ‘‘training-sessions’’ that focus on skills to
implement acquired knowledge in everyday life, for example
medication management and coping strategies. The sessions
are conducted by two trained group-leaders, one medical
doctor or psychologist and one non-academic staff member
(e.g. nurse) as co-therapist. Their attendance of supervision/
intervision sessions assures stable performance quality
(programme overview for patients and relatives see [20]1).
In order to test the hypothesis that this programme
would be effective regarding readmission outcome, com-
pliance, insight, social functioning, quality of life and
other clinical parameters, we designed a small-scaled
randomized controlled clinical trial with a follow-up
period of one year as an explorative study. Both groups—
psychoeducation (PE) and the control condition (CG)—
were offered in addition to routine care. To explore the
therapeutic impact of distinctive psychoeducational ele-
ments (like knowledge transfer), we tested against a
control group that was very similar formatted except for




The study was conducted from November 2007 to January
2010 on the inpatient wards of the Department of General
Psychiatry of the Psychiatric Hospital of the University of
Basel (UPK) in Basel/Switzerland. The study was
approved by the local ethics committee of Basel (Ethi-
kkommission beider Basel).
Inclusion criteria were as follows: at study entry
18–64 years old, inpatient of the UPK with one of the
following diagnoses: Schizophrenia or psychotic disorder
(ICD-10 F2: F20–schizophrenia, F22–persistent delusional
disorder, F23–acute psychotic disorder, F25–schizoaffec-
tive disorder), affective disorder (F31–bipolar disorder,
F32–depressive episode, F33–recurrent depression) or
another severe psychiatric disease like anxiety or person-
ality disorder (F4: neurotic, stress related and somatoform
disorders, F60/61: personality disorders). Patients of the
two latter categories were included only if the index
admission was preceded by at least two hospitalizations or
if the patient was invalid. Written informed consent had to
be on hand. Exclusion criteria were as follows: organic
brain disorder or IQ \ 80, severe addiction disorder, severe
physical comorbidity, pregnancy, lack of competence in
German and ongoing disturbance of the study programme.
The patients (n = 176) were screened in order of their
admission by the main investigator (KR) or another trained
psychiatrist. N = 87 (49.4%) of them were included. Most
of the other 89 patients (50.6%) refused informed consent;
in some cases, the screening procedure revealed before
unknown exclusion criteria. Five patients had to be belat-
edly excluded as protocol violators (PE: n = 3; CG:
n = 2).
The randomization was performed in blocks of 20
patients and stratified with respect to sex (m/w), age
(18–34, 35–49, 50–64 years) and diagnostic group (ICD-10
1 Topics of the 10 sessions for patients are as follows (I = Informa-
tion-session, T = Training- session, D = Discussion): (1) I: Mental
functioning and disorders and the vulnerability-stress-model; (2) I:
The brain and the neurobiological disease-model; (3) T: Coping with
symptoms; (4) I: Treatment options and medication; (5) T: Handling
of medication and coping with side-effects; (6) I: Social aspects of
mental diseases; (7) T: Communication skills; (8) D: Coping with
stigmatization; (9) I: Preparation of discharge and relapse prevention;
(10) T: Detecting early symptoms and ‘‘My individual crisis
strategy’’. The program for relatives consists of 5 sessions including
the topics of sessions 1, 2, 4, 6, 7 and 10 of the patient-version in a
slightly modified form and additionally: Detection and management
of challenging situations (T); Coping with feelings of shame and guilt
(T); Stress reduction and problem solving strategies (T).
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F2; F32/33; F31; F4/F6). An independent external centre
performed the group assignment by a computerized ran-
dom sampling and communicated it back by phone or
email. 43 patients were allocated to PE and 44 patients to
CG. The psychologists, who performed the assessments,
were blinded to the assignment.
Study intervention
In addition to routine treatment, patients of the PE condi-
tion immediately after baseline assessment started the
psychoeducational patient group programme, and patients
of the control condition entered the open ‘‘social-activity-
group’’. After the patients’ discharge from hospital, the
completion of the curriculum as outpatients was recom-
mended. If the patients gave their consent, the relatives
were motivated to join the corresponding family groups.
Structure, contents and characteristics of the psycho-
educational curriculum have been described above [20].1
The control group was likewise led by an academic
professional who was mostly supported by a nurse. The
sessions for patients took place weekly, lasted 90–120 min
each and covered both ‘‘theoretical’’ sessions (conversation
with communication skill training elements, easy concen-
tration training, etc.) as well as physically active collective
leisure time activities (visiting the zoo etc.) and basic social
skill training elements. The spectrum of contents was quite
broad, and only distinctive psychoeducational elements
were excluded. The control group for relatives was
designed as a (bi)weekly conducted closed relaxation and
stress management group, consisting of 4 or 5 sessions, and
managed by a psychologist and physiotherapist.
Outcome measures and assessment instruments
Main outcome criteria were the rehospitalization rate
(percentage of readmitted patients per group, RR), the total
number of rehospitalizations (RA), and accumulated days
in hospital (DIH), the two latter per group per patient, up to
12 months after finishing the programme. Compliance was
assessed by a 14-point self-rating questionnaire (CFB),
which covers not only medication compliance, but also
general aspects as the avoidance of risk factors. The whole
questionnaire can be seen in Fig. 1. The single items were
judged with a Likert scale; the sum score was used for
analysis. It is also available as versions for relatives and
therapists. In this paper, exclusively the score from the
patients’ version is taken into account, because only few
relatives and therapists participated, and the comparable
sample would have become too small.
Secondary outcome variables were the clinical global
impression (CGI) [24], global functioning (GAS) [25],
quality of life (global score of WHO-QOL-BREF, German
version: QOL) [26], insight into the disease (Insight Scale:
IS) [27] and the therapeutic alliance (‘‘Therapeutische
Arbeitsbeziehung’’: TAB) [28] at baseline and at 3- and
12-month follow-up. All these tests are sufficiently vali-
dated, well proven and widely used in clinical research.
The Insight Scale of Markova was used in the modified
form published in 2003 [27] and translated into German by
Fig. 1 Outline of the Compliance-Questionnaire—version for patients
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the corresponding author (KR). Additional qualitative data
were recorded, but will not be discussed in this paper.
Data were recorded at study entry (baseline, BL), after
finishing the programme (which normally took 5–7 weeks,
post-test) and 3, 6 and 12 months after post-test (3MO,
6MO, 12 MO). To cover the whole time course, we report
the data of BL, 3MO and 12MO. Because of the incon-
sistent study compliance of several participants, the
examination dates of 3MO and 12MO differ by up to
4 weeks from the scheduled calendar date. The rehospi-
talization parameters (RR, RA, DIH) were counted retro-
spectively for precisely 3 and 12 months after post-test.
Data analysis and statistical methods
Group differences (e.g. man/woman) were counted by chi-
square test according to Pearson. If the requirements for
using the chi-square test were not given, the Likelihood-
Quotient-Chi-Square was indicated. Student’s t-test was
employed for comparisons of means between PE and CG
concerning illness duration and clinical variables (CGI,
GAS, IS, QOL, TAB and CFB). To test differences con-
cerning rehospitalizations, the more robust Welch-test ‘‘w’’
was used instead of the classical Student’s t-test, because
the criterion for homogeneity of variance was not met [29].
In drop-out analyses, frequency distributions and mean
comparisons concerning the above-mentioned variables
were calculated with the same tests.
To analyse changes over time (baseline-3MO–12MO), a
series of MANOVAs with time as within-subject factor (BL-
12MO, 3MO–12MO) and group as between-subject factor
(PE/CG) was conducted. In case of a diverging sphericity,
degrees of freedom have been corrected according to
Greenhouse-Geiser, the primary degrees of freedom being
indicated by the corresponding Greenhouse-Geiser e.
All findings (mean comparisons, effect sizes, rehospi-
talization rate, etc.) and post hoc analyses refer to the
completers’ data at 3MO and 12MO, respectively.
The criterion for considering results to be statistically
significant was set at a = 0.05. The present study has
explorative character—therefore, following Harris et al.
[30], we set aside the alpha correction.
Furthermore, we were interested in whether consider-
able effect sizes could be found in group comparison.
Therefore, the effect sizes according to Cohen were ana-
lysed [31, 32]. For single measuring points, Cohen‘s d was
counted, applying the following rules: 0.20 C d C 0.49:
small effect size (without practical significance);
0.50 C d C 0.79: medium effect size (moderate practical
significance); d C 0.80: large effect size (high, crucial
importance).
The statistical package SPSS 17.0 for Windows was
used (SPSS Inc.; Chicago, Ill.).
Results
Sample
The CONSORT flow diagram depicts the timeline and
distribution of the study population at any study period
(Fig. 2) [33].
Of 87 initially included patients, 5 (PE: n = 3, CG:
n = 2) were belatedly excluded from the study population
as protocol violators because they withdrew their consent
during the allocation procedure or no longer fulfilled the
inclusion criteria, or exclusion criteria arose (withdrawal of
consent: 2 patients, change of diagnosis: 3 patients).
Of the remaining 82 patients (PE: n = 40; CG: n = 42),
7 patients from PE and 9 patients from CG did not receive
enough (\4/5) group sessions or did not attend any
assessment except at baseline, so that no comparable data
are available. The numbers of dropouts were comparable in
both groups (PE: 7/40, 17.5%; CG: 9/42, 21.4%) and did
not differ considerably from other studies [34]. Most of
them were due to consent withdrawal (PE: n = 7, CG:
n = 8), and one patient committed suicide (CG). There
was no significant difference between dropouts and
completers with respect to relevant socio-demographic or
illness-related variables or baseline scores of the target
variables.
Of the remaining 66 study patients (PE: n = 33, CG:
n = 33), n = 54 stayed in the study until 3MO; however, 3
patients could not be analysed due to missing 3MO-data
(completer-analysis 3MO: PE: n = 27, CG: n = 24).
N = 43 patients were assessed at 12MO (PE: n = 22, CG:
n = 21). Reasons for study discontinuation (PE: n = 11,
CG: n = 12) were mostly withdrawal of consent (PE:
n = 10, CG: n = 9), three suicides (PE: n = 0, CG: n = 3)
and one death by accident (PE: n = 1, CG: n = 0).
Those lost to follow-up (LTFs) have to be considered as
intervention related. They were comparable in PE and CG
concerning absolute numbers and percentage (PE: 10/33,
30.3%, CG: 12/33, 36.4%) and did not exceed accepted
standards [35]. There was a significant group difference
regarding the suicide rate (PE: 0/33, CG: 3/33, v2 = 4.302,
P = 0.038*).
Taking together the ‘‘early’’ and the ‘‘late’’ (LTF-)
dropouts, rates were comparable in both groups. There was
no significant difference between dropped out and
remaining study patients with regard to any relevant socio-
demographic and illness-related variable or the baseline
scores of the clinical target variables, except of insight into
the disease (IS), which was significantly lower in the
dropout population (t = 2.054, P = 0.043*). Once again
the suicide rate—as one reason for drop-out—was signifi-
cantly higher in CG than in PE (PE: 0/40, KG: 4/42,
v2 = 5.548, P = 0.019*).
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It has to be taken into account that some patients (PE: 2
at 3MO, 3 at 12MO; CG: 5 at 3MO, 1 at 12MO) refused to
show up for the assessments, but agreed to fill out the
posted questionnaires. So the clinical assessment by the
examinator (CGI, GAS) is missing in these cases, whereas
the self-rated scores (QOL, IS, etc.) are available. Missing
data for one variable and consecutively varying numbers of
participants for several parameters at the same examination
indicate the fluctuating study compliance of the patients,
who sometimes refused to fill out one or another ques-
tionnaire. Objective variables (readmission outcome
parameters) are constantly available and counted for the
completers of each study visit.
Basic demographic and clinical data of all randomized
patients baseline are presented in Table 1.
The intervention group (PE, n = 40) did not differ from
control group (CG, n = 42) in terms of any relevant socio-
demographic (age, sex, educational level, etc.) or illness-
related data (diagnoses, duration of the disease, etc.), family
involvement during the study or baseline status of any clin-
ical variable (CGI, GAS, etc.). Only the number of previous
hospitalizations was significantly higher in CG (PE:
M = 3.60, SD = 3.89; CG: M = 7.86, SD = 9.31;
t(80) = 2.68, P = 0.009*). In terms of diagnoses, schizo-
phrenia and related disorders (ICD 10-F2), especially
schizophrenia (F20), predominated considerably in both
groups (PE: 60%/50.0%; CG: 71.4%/64.3%), followed by
affective disorders (ICD 10-F3) (PE: 25.0%, CG: 16.7%).
Only few patients with other disorders (F6: PE: 7.1%, CG:
9.5%; F4: PE: 2.5%, CG: 2.4%) were included. There was no
significant group difference concerning family involvement,
the attendance of relatives altogether being poor (PE: 10/40,
CG: 9/42, v2 = 0.147, P = 0.702) (Table 1).
Effects at 3 (3MO)- and 12-months (12MO)–follow-up
Rehospitalization outcome
One main study criterion was the rehospitalization outcome
up to 12 months after the end of the programme. The
tendency switched in favour of the intervention group the
longer the study period lasted: Whereas RR, RA and DIH
were even higher in PE at 3MO, this effect had switched at
12MO. At 12MO, RR for PE was 27.2% (6/22), compared
to 42.9% (9/21) in CG. Less than half as many readmis-
sions per person per group occurred in PE compared to CG
Fig. 2 Consort flow diagram of
the progress through the phases
of the study
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Table 1 Description of study patients
Characteristic PE (N = 40) CG (N = 42) Test Value P d Total (N = 82)
Age, mean, year (SD) 37.7 (9.6) 38.3 (11.3) t-test -0.27 0.79 38.0 (10.4)
Sex, % v2-test 0.51 0.48
male/female 28.3/20.2 32.3/18.1 60/39
Diagnosis (ICD 10), % v2-test 9.94 0.42
Schizophrenia and delusion. Disord. (F2) 65 71.4 68.3
Schizophrenia (F20) 50 64.3 57.3
Delusional disorder (F22) 5 0 2.4
Psychotic episode (F23) 7.5 2.4 4.9
Schizoaffective disorder (F25) 2.5 4.8 3.7
Affective disorder (F3) 25 16.6 20.7
Bipolar affective disorder (F31) 12.5 9.5 11
Depressive episode (F32) 2.5 4.8 3.7
Recurrent depressive disorder (F33) 10 2.4 6.1
Neurotic disorders (F4) 2.5 2.4 2.4
Phobic disorders (F40) 2.5 0 1.2
Obsessive disorders (F42) 0 2.4 1.2
Personality disorders (F6) 7.5 9.5 8.5
Specific personality disorders (F60) 7.5 4.8 6.1
Combined and other pers. Disord. (F61) 0 4.8 2.4
Illness duration, mean ± (SD), y 9.6 (8.8) 12.3 (9.6) t-test -1.33 0.19 11.0 (9.3)
Prev. hospitalizations, mean, d (SD) 3.6 (3.9) 7.9 (9.3) w-test -2.73* \0.01* 5.8 (7.5)
Family status, % v2-test 0.24 1
Married 10 11.9 11
Divorced 15 14.3 14.6
Single 65 64.3 64.6
Partnership 10 9.5 9.8
Family involvement, number 10 9 v2-test 0.15 0.7 19
Habitation, % v2-test 3.41 0.7
Alone 57.1 57.1 58.5
With parents/siblings 12 12 12.2
With partner/child 17.5 12 14.6
With others 2.5 2.4 2.4
Assisted living 0 7.1 3.7
Other 7.5 9.5 8.5
Education, % v2-test 1.82 0.93
Elementary school 37.5 35.7 36.6
Apprenticeship 32.5 40.5 36.6
Secondary school 10 11.9 11
University/of applied science 17.5 9.5 13.5
Other 2.5 2.4 1.2
Psychotropic drugs, mean, number (SD) 2.0 (0.9) 2.24 (1.12) t-test -1.17 0.25 2.1 (1.0)
Dropouts, number 17 21 v2-test 0.46 0.5 38
BL clinical status, mean, score (SD)
CFB 48.1 (7.3) 46.1 (6.1) t-test 1.32 0.19 0.3 47.1 (6.7)
CGI 4.7 (0.7) 4.8 (0.9) t-test -0.61 0.54 0.1 4.8 (0.8)
IS 27.4 (6.7) 28.7 (4.3) t-test -1.08 0.28 0.2 28.1 (5.5)
GAS 55.4 (8.1) 52.0 (8.7) t-test 1.83 0.07 0.4 53.7 (8.5)
QOL 5.9 (2.2) 5.5 (1.9) t-test 0.92 0.36 0.2 5.7 (2.0)
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(PE: 0.45, KG: 1.05), and the DIHs in PE added up for less
than 2/3 of those in CG (PE: 20.3, CG: 31.0). However,
statistical significance was failed (Table 2). Between 3MO
and 12MO, RA and DIH increased considerably stronger in
CG than in PE (increasing number of readmissions between
3MO and 12MO: PE: small effect size, Cohen‘s d = 0.34,
CG medium effect size, Cohen’s d = 0.67; increasing days
in hospital between 3MO and 12MO: PE: small effect size,
Cohen’s d = 0.23, CG: medium effect size, Cohen’s
d = 0.60; Table 3).
Compliance (CFB)
As defined from the applied questionnaire, compliance
was better in PE compared to CG at 3MO and at 12MO
with medium effect sizes (Cohen‘s d[3MO] = 0.64,
Cohen‘s d[12MO] = 0.51). The factor Time showed
large effect size (Cohen‘s d = 0.80) regarding the
improving compliance in PE between BL and 12MO. At
3MO, the group difference was statistically significant
(52.48 vs. 49.52, total N = 50, t(48) = 2.27, P = 0.028*,
Cohen’s d = 0.66) (see Tables 2 and 3, also for the
following results).
Clinical global impression (CGI)
The CGI was used to assess the global clinical impression
of the study patients. The mean value in PE was found to
be better (= lower score) than in CG at 12MO, with med-
ium effect size (Cohen‘s d = 0.54), improving over time
between BL and 12MO with large effect size (Cohen‘s
d = 0.97). The effect was not significant between groups at
any time, but showed a tendency in favour of PE (3MO:
4.13 vs. 4.58, total N = 43, P = 0.193; 12MO: 3.75 vs.
4.40, total N = 40, P = 0.094).
Insight into the disease (Insight Scale, IS)
In spite of PE starting with a slightly lower mean score at
BL, at 3MO, a group difference in favour of PE with
medium effect size (Cohen‘s d = 0.55) arose, which
diminished to a small effect size at 12MO (Cohen‘s
d = 0.24). PE and CG improved over time with large
effect size (3MO–12MO PE: Cohen‘s d = 0.85, CG:
Cohen‘s d = 0.96). There was no significant difference
between PE and control group at any time point.
Global assessment of function (GAS)
The mean value of GAS was found to be higher at 3MO in
PE (medium effect size, Cohen‘s d = 0.56), but the effect
was nearly equalized until 12MO by a medium-sized
improvement in CG between BL and 12MO. The group
differences did not achieve statistical significance at any
study visit.
Quality of life (global score of the WHO-QOL-BREF,
German version)
The global score of the WHO-QOL-BREF was slightly
higher at BL and slightly lower at 3MO in PE versus
CG. Over time (BL–12MO) the QOL score of PE
improved with moderate effect size (Cohen‘s d = 0.67),
and at 12MO, the group difference in favour of PE had
reached a moderate effect size (Cohen‘s d = 0.61).
However, no statistically significant group difference
could be shown.
Therapeutic alliance (‘‘Therapeutisches Arbeitsbu¨ndnis’’,
TAB)
The therapeutic alliance was assessed by the questionnaire
‘‘Therapeutisches Arbeitsbu¨ndnis’’, which was applied in
the version for patients and the one for therapists. In this
paper, we only present the patients’ version, because not all
therapists participated in the study. On a descriptive level,
the mean score rose stronger in CG than in PE, even if
ending up still lower than the latter. However, no signifi-
cant difference was found between the groups (Cohen‘s
d = 0.09 at 3MO and at 12MO).
Table 1 continued
Characteristic PE (N = 40) CG (N = 42) Test Value P d Total (N = 82)
TAB 62.6 (10.6) 58.6 (14.6) t-test 1.44 0.16 0.3 60.5 (12.9)
v2: Fisher’s exact test (except sex, family involvement and dropouts: Pearson’s chi-square test)
Effect sizes (Cohen’s d): Small effect size: 0.49 C d C 0.20; medium effect size: 0.79 C d C 0.50; large effect size: d C 0.80
PE = Intervention Group, CG = Control Group, BL = Baseline, CFB = ’’Compliance-Fragebogen’’ = Compliance-Questionnaire,
CGI = Clinical Global Impression, IS = Insight Scale, GAS = Global Assessment Scale, QOL = Quality of Life-Questionnaire,
TAB = ‘‘Therapeutisches Arbeitsbu¨ndnis’’ = Therapeutic Alliance-Questionnaire
* significant mean difference
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Discussion
This first randomized controlled trial on disorder-inde-
pendent psychoeducation was conducted to test the
hypothesis that a bifocal diagnosis-mixed group pro-
gramme would be effective regarding rehospitalization
outcomes and several clinical variables. We were also
interested in whether distinctive psychoeducational
elements beyond mere unspecific factors (regular meetings
of a professionally conducted group, etc.) caused the
effects.
A strength of our study is the design of the control
group. Its very similar format with an unspecific inter-
vention added on routine care provides a solid foundation
for interpreting the results as specifically induced by dis-
tinctive psychoeducational features. Those PE-specific
elements are namely the interactive transfer of illness- and
treatment-related knowledge and management/coping
strategies, as defined in the Consensus paper of the German
PE-expert-group and by the NICE-GDG [1, 2]. Suchlike
designed control groups are not standard in clinical trials
on psychoeducation, especially not for relatives. It is
obvious that the format of the control condition has an
impact on effect sizes [1, 12].
In sum, the group comparison revealed advantages for
PE. In line with results from previous studies on diagnosis-
specific psychoeducation in schizophrenia, our findings
suggest that the diagnosis-independent form has a favour-
able effect on readmission outcomes. The compliance score
was significantly higher in the intervention group 3 months
after the end of the programme and was accompanied by an
advantage concerning insight and global functioning. In the
following 9 months, the rehospitalization rate, the total
number of readmissions and accumulated days in hospital
increased considerably less in PE, ending up with clear
advantages for PE after 12 months, but significance was
failed. In the same time period, quality of life and the
clinical global impression improved. On a descriptive
level, the group comparison after one year showed
advantages in favour of PE regarding all readmission out-
come parameters as well as the clinical global impression,
quality of life and compliance (Table 2). No clear
Table 2 Clinical target variables at 3MO and 12MO






52.5 (4.5) 49.5 (4.7) 27/23 0.028* 0.6
CGI, mean (SD)a 4.1 (1.1) 4.6 (1.2) 24/19 0.193 0.5
IS, mean (SD)c 29.4 (3.7) 25.9 (8.2) 27/24 0.064 0.6
GAS, mean
(SD)a
60.7 (8.1) 55.5 (10.1) 24/19 0.071 0.6
QOL, mean
(SD)a
6.5 (1.7) 7.0 (1.5) 27/23 0.337 0.3
TAB, mean
(SD)a
65.4 (11.9) 61.2 (14.4) 26/23 0.278 0.1
RA, mean (SD)a 0.22 (0.4) 0.17 (0.4) 27/24 0.626 0.1
DIH, mean
(SD)a
11.4 (27.9) 5.5 (21.8) 27/24 0.405 0.2
RR, frequency
(%)b




53.3 (5.6) 49.4 (9.3) 22/21 0.102 0.5
CGI, mean (SD)a 3.8 (1.2) 4.4 (1.2) 20/20 0.094 0.5
IS, mean (SD)a 32.2 (4.6) 33.4 (5.4) 22/21 0.439 0.2
GAS, mean
(SD)a
59.3 (18.8) 57.4 (12.3) 20/20 0.714 0.1
QOL, mean
(SD)w
7.1 (1.0) 6.4 (1.9) 22/21 0.166 0.6
TAB, mean
(SD)a
66.5 (10.0) 65.5 (11.2) 22/20 0.761 0.1
RA, mean (SD)a 0.5 (0.9) 1.1 (1.8) 22/21 0.178 0.4
DIH, mean
(SD)a
20.3 (47.5) 31.0 (55.9) 22/21 0.503 0.2
RR, frequency
(%)b
6/22 (27.3) 9/21 (42.9) 22/21 0.284
Effect sizes for t-tests (Cohen’s d): small effect size:
0.49 C d C 0.20; medium effect size: 0.79 C d C 0.50; large effect
size: d C 0.80
3MO = follow-up after 3 months, 12MO = follow-up after
12 months, RA = number of readmissions (per person per group),
DIH = accumulated days in hospital (per person per group),
RR = rehospitalization rate (percentage per group)
* significant mean difference
a t-test, b chi-square test, c Welch-test













Values are effect sizes for t-tests (Cohen’ s d). Small effect size:
0.49 C d C 0.20; medium effect size: 0.79 C d C 0.50; large effect
size: d C 0.80
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explanation can be presented for the fluctuating course of
the IS-mean score (worsening from BL to 3MO, then rising
steeply, without significance) and the relatively stronger
improvement over time of the therapeutic alliance (mea-
sured by TAB-patient version) in CG. Concerning the latter
a ceiling effect in PE, which already started with a mean
score above the cut-off (over 60/80 = good therapeutic
alliance), could be one reason.
The drop-out analysis revealed a significantly higher
suicide rate in the control group. Further statistically sig-
nificant group differences especially concerning rehospi-
talization outcome variables, as published in some papers
on diagnosis-specific psychoeducation—nota bene with
participation of at least one key relative as inclusion cri-
terion—failed to appear [36].
However, our study provides similar results as are
presented in recent trials and meta-analyses on psycho-
education for psychotic disorders. In an analysis that
separated PE directed at patients only from family
directed PE, Lincoln et al. showed, that the effect for
reduced relapses and rehospitalizations remained stable
and significant up to one year only in the family-including
setting [12]. This is of crucial importance, because
exclusively patient-focused interventions are by far the
most common setting in clinical reality [16], as is also
reflected by our sample. No integrated effect for PE in
terms of compliance at post-treatment, or functional out-
come or symptoms at 7- to 12-month follow-up could be
shown in this review [12]. Disregarding the partially
different measuring tools and methods our diagnoses-
mixed sample achieved comparable results with slight
disadvantages in some domains but advantages in oth-
ers—especially if the poor attendance (altogether less than
25%) of the relatives is taken into account. Moreover, this
is the first study to show a significant favourable effect of
psychoeducation on the suicide rate [1], which should be
interpreted carefully because this was no defined endpoint
of the trial. Although highly speculative at that time, the
hypothesis seems plausible that the diagnosis-mixed and
interactive approach could help to reduce mutual stig-
matization between patients with different mental disor-
ders as well as associated subjective hopelessness and
insofar be especially promising for severely ill individuals
in this respect.
As limitations, the small sample and the comparatively
short follow-up period should be mentioned. Both are in
line with the exploratory character of the study, and it is
supposed that enlarged designs within future trials will
enhance the effects. The limitation became extremely
obvious in terms of the readmission outcome. Whereas
Pitschel-Walz et al. [36] could report a significant differ-
ence with rehospitalization rates of 21% (PE) versus 38%
(CG), after one year (total N = 163), in our study
significance was failed at 12MO with an RR of 27% (PE)
versus 43% (CG) with a total completer-N of 43. Due to the
small N, it was not possible to differentiate validly between
family-including PE and PE directed at patients alone.
Another limitation is the measurement of compliance,
for which we used a yet not validated questionnaire. We
are aware that this tool may not exceed the validity of a
structured self-report. But as is known from compliance
literature, the results on medication adherence in psychia-
try are mainly based on methods of this or lower quality
[12, 37]. Insofar, our findings are at least not less reliable
than those of previous studies.
Conclusion
Diagnosis-mixed group psychoeducation can be recom-
mended for adults with severe psychiatric diseases. One
advantage is its easier practicability, which may facilitate
the more extensive supply of this cost-economic thera-
peutic option. Its effectiveness regarding readmission out-
comes and relevant clinical variables is comparable to that
of psychosis-specific forms. The design of our control
condition allows to substantially ascribe the improvements
to the distinctive psychoeducational elements.
Further research on diagnosis-independent psychoedu-
cation should concentrate on the effects of the intervention
directed at patients alone, which is the most common set-
ting in clinical routine. If evidence for exclusively patient-
focused PE persistently fails to appear, an adjustment of
the guidelines in the sense of obligatory family involve-
ment—if possible—could be appropriate.
A more subtle analysis in terms of symptom domains or
diagnosis-related outcomes could make it possible to
compare the effects of diagnosis-mixed PE on the level of
syndromes or disorders. It is still unexplored which patients
benefit remarkably more by a group that is specifically
tailored to their personal or illness-dependent characteris-
tics, and exactly which patient-related trait should serve as
the most promising criterion for a diversification of PE
groups. Besides diagnostic categories, for example, sex,
age and the educational background are worthy of con-
sideration. Larger study samples and longer follow-up
periods may allow conclusions on subgroups and promote
statistical significance, respectively.
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